Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARγ signaling pathway

AIM: Resistance to 5-fluorouracil (5-FU) is a major cause of chemotherapy failure in advanced hepatocellular carcinoma (HCC).Rosiglitazone, a peroxisome proliferator-activated receptor γ (PPARγ) agonist, has a crucial role in growth inhibition and induction of apoptosis in several carcinoma cell lin...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Cao, Liang-qi, Wang, Xiao-li, Wang, Qian, Xue, Ping, Jiao, Xing-yuan, Peng, He-ping, Lu, Hai-wu, Zheng, Qiang, Chen, Xi-lin, Huang, Xiao-hui, Fu, Xin-hui, Chen, Jing-song
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2009
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4007181/
https://ncbi.nlm.nih.gov/pubmed/19684609
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/aps.2009.119
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items